Literature DB >> 15452191

Inhibition of phenylephrine-induced cardiomyocyte hypertrophy by activation of multiple adenosine receptor subtypes.

Xiaohong Tracey Gan1, Venkatesh Rajapurohitam, James V Haist, Peter Chidiac, Michael A Cook, Morris Karmazyn.   

Abstract

Plasma adenosine levels are elevated in cardiovascular disease including hypertension and heart failure, and the nucleoside has been proposed to serve as an endogenous antimyocardial remodeling factor. We studied the modulation of phenylephrine-induced hypertrophy by adenosine receptor activation in isolated neonatal cultured ventricular myocytes. Phenylephrine (10 muM) increased cell size by 35% and significantly increased expression of atrial natriuretic peptide. These effects were reduced by the stable adenosine analog 2-chloroadenosine and were completely blocked by the adenosine A(1) receptor agonist N(6)-cyclopentyladenosine (1 microM), the A(2A) receptor agonist 2-p-(2-carboxyethyl)-phenethylamino-5'-N-ethylcarboxamidoadenosine (100 nM), and the A(3) receptor agonist N(6)-(3-iodobenzyl)adenosine-5'-methyluronamide (100 nM). The antihypertrophic effects of all three agonists were completely reversed by their respective antagonists. Phenylephrine significantly up-regulated expression of the immediate early gene c-fos especially within the first 30 min of phenylephrine treatment. These effects were almost completely inhibited by all adenosine receptor agonists. Although phenylephrine also induced early stimulation of both p38 mitogen-activated protein kinase and extracellular signal-regulated kinase, these responses were unaffected by adenosine agonists. The expression of the G-protein regulatory factors RGS2 and RGS4 were increased by nearly 3-fold by phenylephrine treatment although this was completely prevented by adenosine receptor agonists. These agents also blocked the ability of phenylephrine to up-regulate Na/H exchange isoform 1 (NHE1) expression in hypertrophied myocytes. Thus, our results demonstrate an antihypertrophic effect of adenosine acting via multiple receptor subtypes through a mechanism involving down-regulation of NHE1 expression. The ability to prevent regulators of G-protein signaling (RGS) up-regulation further suggests that adenosine receptor activation minimizes signaling which leads to hypertrophic responses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15452191     DOI: 10.1124/jpet.104.073122

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  15 in total

1.  Reduced ability to release adenosine by diabetic rat cardiac fibroblasts due to altered expression of nucleoside transporters.

Authors:  Marzena Podgorska; Katarzyna Kocbuch; Marzena Grden; Andrzej Szutowicz; Tadeusz Pawelczyk
Journal:  J Physiol       Date:  2006-07-27       Impact factor: 5.182

2.  Essential role of obscurin in cardiac myofibrillogenesis and hypertrophic response: evidence from small interfering RNA-mediated gene silencing.

Authors:  Andrei B Borisov; Sarah B Sutter; Aikaterini Kontrogianni-Konstantopoulos; Robert J Bloch; Margaret V Westfall; Mark W Russell
Journal:  Histochem Cell Biol       Date:  2005-10-05       Impact factor: 4.304

Review 3.  Cardiac purinergic signalling in health and disease.

Authors:  Geoffrey Burnstock; Amir Pelleg
Journal:  Purinergic Signal       Date:  2014-12-20       Impact factor: 3.765

4.  Prevention of RhoA activation and cofilin-mediated actin polymerization mediates the antihypertrophic effect of adenosine receptor agonists in angiotensin II- and endothelin-1-treated cardiomyocytes.

Authors:  Asad Zeidan; Xiaohong Tracey Gan; Ashley Thomas; Morris Karmazyn
Journal:  Mol Cell Biochem       Date:  2013-10-06       Impact factor: 3.396

5.  Interference with ERK(Thr188) phosphorylation impairs pathological but not physiological cardiac hypertrophy.

Authors:  Catharina Ruppert; Katharina Deiss; Sebastian Herrmann; Marie Vidal; Mehmet Oezkur; Armin Gorski; Frank Weidemann; Martin J Lohse; Kristina Lorenz
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-15       Impact factor: 11.205

6.  Adenosine A2A receptor signaling regulation of cardiac NADPH oxidase activity.

Authors:  David Ribé; David Sawbridge; Sapna Thakur; Martin Hussey; Catherine Ledent; Ian Kitchen; Susanna Hourani; Jian-Mei Li
Journal:  Free Radic Biol Med       Date:  2008-01-05       Impact factor: 7.376

7.  Adenosine A1 receptor activation attenuates cardiac hypertrophy and fibrosis in response to α1 -adrenoceptor stimulation in vivo.

Authors:  S-L Puhl; A Kazakov; A Müller; P Fries; D R Wagner; M Böhm; C Maack; Y Devaux
Journal:  Br J Pharmacol       Date:  2015-11-16       Impact factor: 8.739

Review 8.  In vitro effects of exercise on the heart.

Authors:  Dane J Youtz; Michael C Isfort; Clayton M Eichenseer; Timothy D Nelin; Loren E Wold
Journal:  Life Sci       Date:  2014-09-08       Impact factor: 5.037

9.  CD73-TNAP crosstalk regulates the hypertrophic response and cardiomyocyte calcification due to α1 adrenoceptor activation.

Authors:  Xiaohong Tracey Gan; Seiichi Taniai; Ganjian Zhao; Cathy X Huang; Thomas J Velenosi; Jenny Xue; Bradley L Urquhart; Morris Karmazyn
Journal:  Mol Cell Biochem       Date:  2014-06-04       Impact factor: 3.396

10.  Group VIA phospholipase A2 (iPLA2beta) participates in angiotensin II-induced transcriptional up-regulation of regulator of g-protein signaling-2 in vascular smooth muscle cells.

Authors:  Zhongwen Xie; Ming C Gong; Wen Su; John Turk; Zhenheng Guo
Journal:  J Biol Chem       Date:  2007-07-05       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.